Vijay Kasturi

520 total citations
33 papers, 395 citations indexed

About

Vijay Kasturi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Vijay Kasturi has authored 33 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Vijay Kasturi's work include Renal cell carcinoma treatment (11 papers), Lung Cancer Treatments and Mutations (8 papers) and Renal and related cancers (6 papers). Vijay Kasturi is often cited by papers focused on Renal cell carcinoma treatment (11 papers), Lung Cancer Treatments and Mutations (8 papers) and Renal and related cancers (6 papers). Vijay Kasturi collaborates with scholars based in United States, France and Germany. Vijay Kasturi's co-authors include James L. Gulley, Sebastian Bauer, Anja von Heydebreck, Hariharan Subramanian, Christopher Hoimes, Deborah Jean Lee Wong, Rainer Claus, Christophe Le Tourneau, Martin Wermke and Vikram K. Chand and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and The Oncologist.

In The Last Decade

Vijay Kasturi

31 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vijay Kasturi United States	9	220	110	103	86	77	33	395
Nicholas J. Giacalone United States	15	258 1.2×	83 0.8×	295 2.9×	173 2.0×	216 2.8×	25	721
J. Varthalitis Greece	9	280 1.3×	97 0.9×	111 1.1×	114 1.3×	102 1.3×	17	421
Jayme B. Stokes United States	9	468 2.1×	146 1.3×	144 1.4×	119 1.4×	117 1.5×	14	644
Martina Torchio Italy	13	300 1.4×	128 1.2×	80 0.8×	69 0.8×	141 1.8×	30	481
Stanley E. Waintraub United States	7	153 0.7×	56 0.5×	18 0.2×	30 0.3×	32 0.4×	21	290
Alessio Fabozzi Italy	13	264 1.2×	90 0.8×	63 0.6×	108 1.3×	221 2.9×	32	507
Maobin Meng China	19	232 1.1×	151 1.4×	141 1.4×	239 2.8×	231 3.0×	46	778
P. Nelli Italy	10	213 1.0×	32 0.3×	31 0.3×	142 1.7×	32 0.4×	29	377
Rebecca Tay United Kingdom	11	412 1.9×	61 0.6×	68 0.7×	211 2.5×	88 1.1×	22	512
Amedeo Sciarra Switzerland	13	153 0.7×	63 0.6×	152 1.5×	64 0.7×	68 0.9×	33	437

Countries citing papers authored by Vijay Kasturi

Since Specialization

Citations

This map shows the geographic impact of Vijay Kasturi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vijay Kasturi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vijay Kasturi more than expected).

Fields of papers citing papers by Vijay Kasturi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vijay Kasturi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vijay Kasturi. The network helps show where Vijay Kasturi may publish in the future.

Co-authorship network of co-authors of Vijay Kasturi

This figure shows the co-authorship network connecting the top 25 collaborators of Vijay Kasturi. A scholar is included among the top collaborators of Vijay Kasturi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vijay Kasturi. Vijay Kasturi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Beckermann, Kathryn E., Aviva G. Asnis-Alibozek, Michael B. Atkins, et al.. (2024). Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The Oncologist. 29(3). 254–262. 8 indexed citations

Li, Daneng, Farshid Dayyani, Devalingam Mahalingam, et al.. (2023). Final results of a phase 1b/2 study of tivozanib in combination with durvalumab in patients with advanced hepatocellular carcinoma in both previously untreated patients and patients progressing on atezolizumab and bevacizumab.. Journal of Clinical Oncology. 41(4_suppl). 585–585. 2 indexed citations

Barata, Pedro C., Alex Chehrazi‐Raffle, Kimberly D Allman, et al.. (2023). Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial. The Oncologist. 28(10). 894–900. 2 indexed citations

Zengin, Zeynep Büşra, Sumanta K. Pal, David F. McDermott, et al.. (2022). Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. Clinical Genitourinary Cancer. 20(6). 553–557. 3 indexed citations

Meza, Luís, David F. McDermott, Bernard Escudier, et al.. (2022). Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3. The Oncologist. 28(3). e167–e170. 2 indexed citations

Iyer, Renuka, Daneng Li, Farshid Dayyani, et al.. (2022). Phase 1b/2 study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive): Efficacy results in previously untreated patients.. Journal of Clinical Oncology. 40(4_suppl). 462–462. 1 indexed citations

Dayyani, Farshid, Daneng Li, Julie Rowe, et al.. (2022). A phase 1b/2, open-label study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive).. Journal of Clinical Oncology. 40(4_suppl). TPS499–TPS499. 1 indexed citations

Li, Daneng, Julie Rowe, Vijay Kasturi, et al.. (2022). A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE). Future Oncology. 18(40). 4465–4471. 6 indexed citations

Choueiri, Toni K., Laurence Albigès, Rana R. McKay, et al.. (2022). TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.. Journal of Clinical Oncology. 40(16_suppl). TPS4605–TPS4605. 2 indexed citations

10.

Zheng, Ying, et al.. (2021). Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy. Advances in Therapy. 38(5). 2644–2661. 1 indexed citations

11.

Walker, John, Célèste Lebbé, Giovanni Grignani, et al.. (2020). Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. Journal for ImmunoTherapy of Cancer. 8(1). e000313–e000313. 52 indexed citations

12.

Kapetanakis, Venediktos, Michael Schlichting, K. Jack Ishak, et al.. (2020). Comparing progression-free survival (PFS) in second-line (2L) urothelial carcinoma (UC) treatments from single-arm trials: Importance of using appropriate methods.. Journal of Clinical Oncology. 38(6_suppl). 573–573. 1 indexed citations

13.

Keilholz, Ulrich, Janice M. Mehnert, Sebastian Bauer, et al.. (2019). Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. Journal for ImmunoTherapy of Cancer. 7(1). 12–12. 71 indexed citations

14.

Patel, Manish R., James L. Gulley, Keun‐Wook Lee, et al.. (2019). Avelumab treatment in metastatic urothelial carcinoma: Association between early response and durable outcomes in the phase Ib JAVELIN Solid Tumor Study.. Journal of Clinical Oncology. 37(7_suppl). 429–429. 1 indexed citations

15.

Nathan, Paul, Vijay Kasturi, Luc Dirix, et al.. (2018). Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad-hoc expanded access program (EAP). Annals of Oncology. 29. viii460–viii461. 2 indexed citations

16.

Tourneau, Christophe Le, Christopher Hoimes, Corrine Zarwan, et al.. (2018). Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. Journal for ImmunoTherapy of Cancer. 6(1). 111–111. 122 indexed citations

17.

Kasturi, Vijay, John R. Eckardt, & F. Anthony Greco. (2004). A preliminary retrospective analysis of weekly topotecan in recurrent small-cell lung cancer. Journal of Clinical Oncology. 22(14_suppl). 7359–7359. 2 indexed citations

18.

19.

Breathnach, Oscar S., Vijay Kasturi, Frederic J. Kaye, et al.. (2002). Phase II Neoadjuvant Trial of Paclitaxel by 96-Hour Continuous Infusion (CIVI) in Combination With Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non–Small-Cell Lung Cancer. American Journal of Clinical Oncology. 25(3). 269–273. 2 indexed citations

20.

Kasturi, Vijay, Stephen C. Piscitelli, E K Russell, et al.. (1998). Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.. PubMed. 4(9). 2095–102. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact